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Houston, Houston, TX, USAA B S T R A C TBackground: Previous economic evaluations compared speciﬁc che-
motherapy agents using input parameters from clinical trials and
resource utilization costs. Cost-effectiveness of treatment groups
(drug classes) using community-level effectiveness and cost data,
however, has not been assessed for elderly patients with breast
cancer. Objective: To assess the cost-effectiveness of chemotherapy
regimens by age and disease stage under “real-world” conditions for
patients with breast cancer. Methods: The Surveillance Epidemiology
and End Results-Medicare data were used to identify patients with
breast cancer with American Joint Committee on Cancer stage I/II/IIIa,
hormone receptor–negative (estrogen receptor–negative and proges-
terone receptor–negative) patients from 1992 to 2009. Patients were
categorized into three adjuvant treatment groups: 1) no chemother-
apy, 2) anthracycline, and 3) non–anthracycline-based chemotherapy.
Median life-years and quality-adjusted life-years (QALYs) were meas-
ured using Kaplan-Meier analysis and were evaluated against average
total health care costs (2013 US dollars). Results: A total of 4575
patients (propensity score–matched) were included for the primaryee front matter & 2015 Published by Elsevier Inc.
(ISPOR).
.1016/j.jval.2015.08.008
airson@uth.tmc.edu.
ondence to: David R. Lairson, University of Texas Sanalysis. The anthracycline group experienced 12.05 QALYs and mean
total health care costs of $119,055, resulting in an incremental cost-
effectiveness ratio of $7,688 per QALY gained as compared with the no
chemotherapy group (QALYs 7.81; average health care cost $86,383).
The non–anthracycline-based group was dominated by the anthracy-
cline group with lower QALYs (9.56) and higher health care costs
($122,791). Base-case results were found to be consistent with the
best-case and worst-case scenarios for utility assignments. Incremen-
tal cost-effectiveness ratios varied by age group (range $3,790–$90,405
per QALY gained). Conclusions: Anthracycline-based chemotherapy
was found cost-effective for elderly patients with early stage (stage I,
II, IIIa) breast cancer considering the US threshold of $100,000 per
QALY. Further research may be needed to characterize differential
effects across age groups.
Keywords: breast cancer, chemotherapy, cost-effectiveness, cost-utility.
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Pharmacoeconomics and Outcomes Research (ISPOR).Introduction
Analysts have called for economic evaluation of alternative
treatment strategies for speciﬁc types of patients with breast
cancer [1,2]. Previous research has examined the cost of treating
breast cancer in the United States and the cost-effectiveness of
alternative treatments, primarily associated with alternative drug
regimens [3–5]. Economic evaluations of breast cancer treatment
are often based on hypothetical cohorts and/or modeling of
disease progression [4–9], in which health outcomes and costs
are based on literature-derived parameters [4–9]. Age has rarely
been examined as a factor in the assessment of cost-
effectiveness of chemotherapy for patients with breast cancer
[5]. Surveillance Epidemiology, End Results (SEER)-Medicare data
have been used to estimate the cost of colorectal cancertreatment [10,11] but not to examine the cost-effectiveness of
chemotherapy stratiﬁed by age group and stage of breast cancer.
The present study advances the ﬁeld by using a large, multiyear
cohort to assess the cost-effectiveness of chemotherapy regi-
mens by age and disease stage under “real-world” conditions for
patients with breast cancer.
It is important to know whether the survival beneﬁt associ-
ated with the administration of adjuvant chemotherapy in
randomized clinical trials remains evident in community-based
practices for elderly patients with breast cancer. Limited evidence
exists (from clinical trials) for the beneﬁt of chemotherapy in
women 70 years or older with node-positive tumors or node-
negative tumors of more than 1 cm [12–14]. The latest review [14]
stated, “In subgroup analyses for trials of standard or near-
standard cyclophosphamide, methotrexate, and ﬂuorouracilon behalf of International Society for Pharmacoeconomics and
chool of Public Health, 1200 Hermann Pressler Street, RAS E-307,
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appeared inversely related to age and nodal status, but again
appeared independent of ER status.” Their Web Appendix (Table
P14) showed that the relative risk for mortality was 0.59 for
women younger than 45 years, 0.66 for women aged 45 to 54
years, and 0.87 for women aged 55 to 69 years. In their study, the
overall effect of chemotherapy in those 65 years or older com-
bined was signiﬁcant at 0.76 for mortality reduction. A signiﬁcant
age-chemotherapy interaction was clear.
Muss [15] and Muss et al. [16,17] reported on the efﬁcacy of
chemotherapy in older patients. In these studies, all patients
were combined as 65 years or older versus younger than 65 years.
Although the authors concluded that there was no association
between age and disease-free survival, it was not clear that the
efﬁcacy of chemotherapy was the same in those aged 70 to 74 or
75 to 79 years as in those aged 65 to 69 years. A recent
observational study found, however, that for women 80 years or
older, adjuvant chemotherapy was not effective except in a few
patients who received adriamycin-cyclophosphamide; the mor-
tality risk was signiﬁcantly reduced for those aged 80 to 84 years
[18].
One explanation for no statistically signiﬁcant chemotherapy-
associated survival beneﬁt for women with breast cancer aged 70
years or older is the small number of elderly patients enrolled in
clinical trials. These results, however, are not consistent with
ﬁndings for chemotherapy-associated survival beneﬁts for older
patients with ovarian, lung, and colon cancer where the number
of elderly patients in clinical trials is also small [19–21]. The large
number of cases in this study enables us to determine whether
chemotherapy beneﬁts patients in this population.
This study compare life-years saved and quality-adjusted life-
years (QALYs) saved for three alternative treatment regimens (no
chemotherapy, anthracycline [doxorubicin or epirubicin]-based
chemotherapy, and non–anthracycline-based chemotherapy).
With quality-of-life adjustments assigned for cancer stage, recur-
rence, and debilitating adverse effects, the study considers both
the positive and negative outcomes of chemotherapy and con-
trasts these outcomes with total health care cost. SEER-Medicare
data are valuable for studying cancer outcomes because chemo-
therapy drugs are among the few drugs that are covered by the
Medicare program over the past two decades, thus allowing
chemotherapy-speciﬁc cost-effectiveness analyses. The results
of economic evaluations have important clinical implications for
physicians treating patients with cancer, for developing clinical
practice guidelines, and for identifying critical target areas to be
tested in future clinical trials. The potential impact of the present
study is signiﬁcant for treating patients with breast cancer 65
years or older in at least 16 of the regions in the United States
captured in SEER and potentially generalizable to other areas.Methods
Data Source, Population, and Chemotherapy Regimens
The SEER-Medicare–linked data provide information on patient
and tumor characteristics and resource utilization information in
65 years or older patients with cancer. Accuracy and validity of
these data have previously been established [22]. Women 65 to 94
years old diagnosed with breast cancer as the ﬁrst primary tumor
without other primary tumors from January 1992 to December
2009 were included. Women were excluded if the diagnosis was
based on autopsy, death certiﬁcate, or if they died within 90 days
of diagnosis. Enrollment in both Medicare parts A and B without
any health maintenance organization enrollment from the time
of diagnosis to death or the end of the study (December 31, 2010)
was required. A total of 14,610 women diagnosed with AmericanJoint Committee on Cancer stage I, II, or III A who had undergone
either breast-conserving surgery or mastectomy for estrogen
receptor and progesterone receptor–negative tumors from 16
SEER areas were included.
Propensity score matching was conducted to reduce selection
bias, which is inherent to observation studies. A propensity score
of receiving chemotherapy for each treatment group was calcu-
lated using multinomial logistic regression [23]. We also applied
the inverse probability of treatment weighting (IPTW) method
that uses the inverse of probabilities estimated from multinomial
logistic regression as a weight to obtain the population estimate;
however, a major limitation of this approach is high sensitivity to
these weights and hence the probabilities need to be estimated
very well [24–26]. The probabilities are as good as the covariates
used to estimate them, and the covariates available using large
administrative databases such as SEER-Medicare data are limited.
Thus, the propensity score matching approach was selected as
the primary analysis and IPTW as the secondary analysis.
Although precision may be improved by selecting variables on
the basis of their association with outcomes irrespective of the
exposure [27], variable selection was based on regression cova-
riates that have been found to be associated with chemotherapy
selection [28–30], and were available in our data (i.e., age, race,
marital status, tumor stage, tumor size, node positive/negative,
tumor grade, type of surgery, radiation, comorbidity score, socio-
economic status, region, and year of diagnosis). A 1:1:1 propensity
score matching was performed using the nearest-neighbor
method [31]. The algorithm matches two treatment groups
simultaneously with the referent group (no chemotherapy). All
matched pairs of patients were within the prespeciﬁed caliper
distance of 0.05. Chi-square test and standardized difference
were used to assess the balance of covariates between the
treatment groups [32–34]. An effect size of less than 0.1 indicated
negligible difference between comparison groups [33]. A lifetime
time horizon with maximum follow-up until December 2010 was
applied.
Patients were placed into three treatment groups—no chemo-
therapy, anthracycline-based chemotherapy, and non–anthracy-
cline-based chemotherapy—on the basis of Medicare claim codes
identiﬁed within 12 months following diagnosis. Anthracycline-
based chemotherapy was deﬁned using Healthcare Common
Procedure Coding System codes for doxorubicin (J9000, J9001,
J9010) and epirubicin (J9178). Non–anthracycline-based chemo-
therapy was deﬁned using chemotherapy-associated codes
except for epirubicin and doxorubicin (Healthcare Common
Procedure Coding System codes 96400-96549, J9002-J9009, J9011-
J9177, J9179-J9999, and Q0083-Q0085; International Classiﬁcation of
Diseases, Ninth Revision, Clinical Modiﬁcation codes V58.1, V66.2, and
V67.2; International Classiﬁcation of Diseases, Ninth Revision, Clinical
Modiﬁcation procedure code 9925) [35–37].
Effectiveness and Cancer Phases
Life-years and QALYs gained were the treatment outcomes.
Patient survival times were deﬁned as days from diagnosis to
death or end of study and were categorized into three phases:
initial, continuing, and terminal [38]. Health state utilities were
obtained from the literature for assignment to the speciﬁc
disease phase, for adjuvant chemotherapy receipt (with or with-
out major adverse event), and for time since diagnosis and
disease recurrence (Table 1) [39,40]. Health state utilities for the
initial phase were based on the receipt of any chemotherapy and
the severity of chemotherapy-related adverse events. Adverse
events were evaluated as “moderate” or “severe” if they were
reported in outpatient and inpatient claims, respectively [41].
Appendix Table 1 in Supplemental Materials found at http://dx.
doi.org/10.1016/j.jval.2015.08.008 presents a detailed list of
Table 1 – Utility weights assigned to various disease phases in base-case and alternative scenarios.
Treatment phase Base-case scenario Best-case scenario Worst-case scenario
Initial phase (ﬁrst year)
No adjuvant chemotherapy 0.85 0.85 0.58
Adjuvant chemotherapy—no or moderate toxicity 0.78
Adjuvant chemotherapy—severe toxicity 0.58
Continuing phase
Stage I—year 2–5 0.91 0.99 0.84
Stage I—year 6þ 0.99
Stage II—year 2þ 0.87
Stage III—year 2þ 0.84
Recurrence NA NA 0.58
Terminal phase (last year of life) 0.23 0.3 0.16
NA, not applicable.
* Utility values were obtained from the literature [38,39].
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chemotherapy, the initial phase was subdivided into four 3-
month subphases and a patient was considered to have an
adverse event during the subphase if at least one claim for a
chemotherapy adverse event was reported in that subphase.
Continuing phase utilities were based on breast cancer stage
and time since diagnosis. In an alternate scenario (worst case) for
the continuing phase, a recurrence was identiﬁed if there was a
gap in chemotherapy for more than 4 months ( 15 days) in the
continuing phase and a recurrence utility was assigned for the
remaining continuing phase [42].
QALYs for each phase were computed by multiplying the
phase survival time with the associated utility, and total QALYs
were calculated by summing phase-speciﬁc QALYs. A nonpara-
metric Kaplan-Meier analysis was conducted to obtain median
life-years and QALYs. In our preliminary analysis, mean effec-
tiveness was estimated but we were unable to generate survival
bootstrap replicates for computing conﬁdence intervals for the
mean. Median effectiveness was selected, consistent with pre-
vious economic evaluations [43,44], and is more often used in
survival studies [45]. A 3% annual discount rate was applied to
life-years and QALYs. Similar analyses were conducted for alter-
native scenarios 1) best case: using the most optimistic utility
value and 2) worst case: using the most conservative utility value
(Table 1) and for age groups (65–69, 70–74, 75–79, and 80þ years).
For the age group 65 to 69 years, median survival was not
observed; therefore, parametric regression was used to estimate
the median life-years and median QALYs. Log-normal distribu-
tion was used for the parametric regression as the best ﬁt for the
data when compared with weibull, log logistic, and exponential
distribution using the Akaike information criterion [46].
Cost Analysis
Medicare amount paid for each claim was used to represent a US
national payer perspective for health care costs. Total health care
costs and phase-speciﬁc costs per month were estimated from
diagnosis until death or end of study using claims for inpatient
services, outpatient visits and procedures, physician services,
skilled nursing facility, hospice, and durable medical equipment.
Total health care cost for each patient was calculated by dividing
the patient time into initial, continuing, and terminal phases.
Costs incurred during each of these phases were aggregated to
obtain phase-speciﬁc costs, which were summed to obtain the
total health care cost for each patient. The effect of censoring on
the cost estimates and incremental cost-effectiveness ratios
(ICERs) was addressed in a sensitivity analysis by assigning age-
speciﬁc median survival to patients who had not died by the end
of study, and for the unobserved time (i.e., age-speciﬁc mediansurvival – observed time), we allocated age-speciﬁc per month
continuing/terminal phase costs and thereby estimated
censoring-adjusted total health care cost for each patient. Cost
data from 1992 to 2010 were adjusted for geographical location
and inﬂation using price adjusters developed by Brown et al. [47].
Price adjusters were matched with patient’s county at diagnosis
using the registry code variable and Federal Information Process-
ing Standard county code from the SEER data. Price adjusters
allowed the conversion of costs to 2009 US dollars, and adjust-
ment to 2013 US dollars was calculated using medical care
consumer price index [48]. Costs were discounted at 3% per
annum [49,50].Cost-Effectiveness Analysis
ICERs were calculated for anthracycline-based chemotherapy
versus no chemotherapy and non–anthracycline-based chemo-
therapy versus anthracycline-based chemotherapy using life-
years and QALYs gained. As ICER is a ratio statistic, 95%
conﬁdence intervals were approximated from 5000 bootstrap
samples. Cost-effectiveness acceptability curves were generated
using the proportion of bootstrap sample ICERs that fell below a
range of willingness-to-pay (WTP) thresholds. ICERs were calcu-
lated for best-case and worst-case scenarios and for different age
groups. A secondary analysis calculated ICERs on the basis of
data from the entire sample of 14,610 patients (unmatched
cohort) using the IPTW approach assuming log-normal distribu-
tion for survival time [34,51].Results
The 1:1:1 nearest-neighbor–matched sample included a total of
4575 patients, with 1525 patients in each treatment group
(Table 2). Chi-square tests and standardized difference indicate
that the three treatment groups were well balanced for patient
and tumor characteristics (tumor stage, tumor size, node pos-
itive/negative, and tumor grade), geographic areas, and year of
diagnosis. Appendix Table 2 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2015.08.008 presents total phase-
speciﬁc health care costs per month for each treatment group.
Overall, the highest per month cost was observed in the terminal
phase (range $5140–$6554), followed by the initial phase (range
$2499–$4539) and then the continuing phase (range $985–$1336).
Costs for the anthracycline-based chemotherapy group were the
highest during the initial ($4539) and terminal ($6554) phase,
whereas costs were highest for non–anthracycline-based chemo-
therapy group during the continuing phase ($1336).
Table 2 – Distribution of characteristics by chemotherapy status in patients with breast cancer.
Characteristic (total
N ¼ 4575)
n (%) P
value
Standardized
difference
No chemotherapy
(N ¼ 1525)
Non– anthracycline-
based chemotherapy
(N ¼ 1525)
Anthracycline-
based
chemotherapy
(N ¼ 1525)
Age (y) 0.480 0.07
65–69 568 (37.3) 558 (36.6) 578 (37.9)
70–74 501 (32.9) 513 (33.6) 487 (31.9)
75–79 362 (23.7) 335 (22.0) 344 (22.6)
80þ 94 (6.2) 119 (7.8) 116 (7.6)
Race/ethnicity 0.376 0.03
White 1254 (82.273) 1272 (83.4) 1252 (82.1)
Black 184 (12.1) 171 (11.2) 168 (11.0)
Other 87 (5.7) 82 (5.4) 105 (6.9)
Marital status 0.916 0.03
Married 750 (49.2) 774 (50.8) 759 (49.8)
Unmarried 732 (48.0) 706 (46.3) 720 (47.2)
Unknown 43 (2.8) 45 (3.0) 46 (3.0)
Tumor AJCC stage 0.937 0.02
Stage I 603 (39.5) 593 (38.9) 582 (38.2)
Stage II 809 (53.1) 812 (53.3) 822 (53.9)
Stage III 113 (7.4) 120 (7.9) 121 (7.9)
Tumor size (cm) 0.745 0.07
o1.0 119 (7.8) 134 (8.8) 122 (8.0)
1.0–o2.0 559 (36.66) 537 (35.21) 542 (35.5)
2.0–o4.0 619 (40.59) 599 (39.28) 618 (40.5)
4þ/unknown 228 (15.0) 255 (16.7) 243 (15.9)
Node positive/negative 0.532 0.06
Positive 460 (30.2) 489 (32.1) 480 (31.5)
Negative 995 (65.3) 953 (62.5) 964 (63.2)
Unknown 70 (4.6) 83 (5.4) 81 (5.3)
Tumor grade 0.546 0.05
Well/moderately
differentiated
377 (24.7) 372 (24.4) 385 (25.3)
Poorly/
undifferentiated
1,066 (69.9) 1086 (71.2) 1055 (69.2)
Unknown/missing 82 (5.4) 67 (4.4) 85 (5.6)
Surgery 0.914 0.01
Breast-conserving
surgery
747 (49.0) 738 (48.4) 736 (48.3)
Mastectomy 778 (51.0) 787 (51.6) 789 (51.7)
Radiation 0.840 0.01
Yes 913 (59.9) 904 (59.3) 897 (58.8)
No 612 (40.1) 621 (40.7) 628 (41.2)
Comorbidity scores 0.851 0.03
0 1,018 (66.8) 1,036 (67.9) 1,034 (67.8)
1 336 (22.0) 332 (21.8) 338 (22.2)
Z2 171 (11.2) 157 (10.3) 153 (10.0)
SES (poverty) 0.792 0.04
First (low SES) 413 (27.1) 430 (28.2) 440 (28.9)
Second 365 (23.9) 366 (24.0) 382 (25.1)
Third 383 (25.1) 362 (23.7) 358 (23.5)
Fourth (high SES) 364 (23.9) 367 (24.1) 345 (22.6)
SEER areas 0.537 0.06
Midwest 276 (18.1) 263 (17.3) 248 (16.3)
Northeast 283 (18.6) 319 (20.9) 295 (19.3)
South 299 (19.6) 305 (20.0) 316 (20.7)
West 667 (43.7) 638 (41.8) 666 (43.7)
Year of diagnosis 0.997 0.11
1992 23 (1.5) 20 (1.3) 27 (1.8)
1993 29 (1.9) 23 (1.5) 23 (1.5)
1994 15 (1.0) 22 (1.4) 22 (1.4)
continued on next page
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Table 2 – continued
Characteristic (total
N ¼ 4575)
n (%) P
value
Standardized
difference
No chemotherapy
(N ¼ 1525)
Non– anthracycline-
based chemotherapy
(N ¼ 1525)
Anthracycline-
based
chemotherapy
(N ¼ 1525)
1995 44 (2.9) 37 (2.4) 35 (2.3)
1996 39 (2.6) 29 (1.9) 34 (2.2)
1997 37 (2.4) 52 (3.4) 37 (2.4)
1998 47 (3.1) 53 (3.5) 48 (3.2)
1999 61 (4.0) 54 (3.5) 57 (3.7)
2000 105 (6.9) 110 (7.2) 103 (6.8)
2001 116 (7.6) 116 (7.6) 120 (7.9)
2002 134 (8.8) 125 (8.2) 143 (9.4)
2003 124 (8.1) 122 (8.0) 123 (8.1)
2004 112 (7.3) 112 (7.3) 104 (6.8)
2005 127 (8.3) 114 (7.5) 126 (8.3)
2006 162 (10.6) 173 (11.3) 159 (10.4)
2007 149 (9.8) 148 (9.7) 147 (9.6)
2008 99 (6.5) 102 (6.7) 98 (6.4)
2009 102 (6.7) 113 (7.4) 119 (7.8)
AJCC, American Joint Committee on Cancer; SEER, Surveillance Epidemiology, End Results; SES, socioeconomic status.
* The small number of cases with unknown tumor size was combined with the tumor size 4þ category, which was reported because of the
Data User Agreement rule that requires no number of cases in each cell o11.
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ICERs for the three treatment groups with mean values for costs
and median effectiveness measures. Total health care costs were
highest for the non–anthracycline-based chemotherapy group
($122,791) as compared with anthracycline-based chemotherapy
group ($119,055) and no chemotherapy group ($86,383). Patients
on anthracycline-based chemotherapy incurred less health care
cost and gained more years of life than did patients on non–
anthracycline-based chemotherapy. Median life-years for the
anthracycline group were 10.97 and 9.58 for the non–anthracy-
cline-based group compared with 8.37 for the no chemotherapy
group. Median QALYs for the anthracycline-based group and the
non–anthracycline-based group were 12.05 and 9.56, respectively,
compared with 7.81 for the no chemotherapy group. The ICER for
anthracycline-basd group (vs. the no chemotherapy group) was
$12,566 per life-year gained and $7688 per QALY gained, respec-
tively. The non–anthracycline-based group was dominated (more
costly and less effective) compared with the anthracycline group.
Results for best-case and worst-case scenarios were similar toTable 3 – Effectiveness and cost-effectiveness for chemo
Chemotherapy
treatment group
Effectiveness To
ca
Median life-
years (95% CI)
Median QALY
(95% CI)
M
No chemotherapy 8.37 (7.79–9.10) 7.81 (7.19–8.63) 86
Anthracycline-
based
10.97 (9.51–14.01) 12.05 (9.92– NA) 119
Non–anthracycline-
based
9.58 (9.05–10.43) 9.56 (8.19–10.57) 122
CI, conﬁdence interval; ICER, incremental cost-effectiveness ratio; NA, n
* Treatment groups arranged in ascending order of cost.
† 2013 US dollars.results for the base-case analysis; ICERs per QALY gained were
$7969 and $8783 for the best-case and worst-case scenario,
respectively (data not shown). Results were similar to results of
the base-case analysis using mean effectiveness and the IPTW
approach (data not shown).
All bootstrap samples comparing anthracycline-based chemo-
therapy versus no chemotherapy were in the northeast quadrant
(more costly and more effective) of the cost-effectiveness plane
(data not shown). Cost-effectiveness acceptability curves demon-
strate that anthracycline-based chemotherapy was nearly 100%
cost-effective at a WTP threshold of $50,000 as compared with no
chemotherapy Fig. 1.
Table 4 presents the effectiveness and cost-effectiveness of
chemotherapy treatments stratiﬁed by age, and Appendix Table 6
in Supplemental Materials found at http://dx.doi.org/10.1016/j.
jval.2015.08.008 presents the patient and tumor characteristics by
age. Overall, as age increases, the effectiveness of chemotherapy
decreased (Fig. 2). The median QALYs for anthracycline-based
chemotherapy for the 65 to 69 years age group was 21.91 QALYstherapy treatment groups.
tal Health
re cost† ($)
ICER ($)
ean (SE) Per median life-year
gained (95% CI)
Per median QALY
gained (95% CI)
,383 (2157.09) – –
,055 (2327.32) 12,566 (5,617–36,599) 7,688 (5,398–18,429)
,791 (2894.94) Dominated Dominated
ot available; QALY, quality-adjusted life-year; SE, standard error.
Fig. 1 – Cost-effectiveness acceptability curve—All age
groups. QALY, quality-adjusted life-year. (Color version of
ﬁgure available online).
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 0 7 0 – 1 0 7 8 1075versus 4.79 QALYs for the 80þ years age group. Compared with no
chemotherapy, anthracycline-based chemotherapy had an ICER of
$6691 per life-year gained and $3790 per QALY gained for the 65 to
69 years age group; $12,500 per life-year gained and $10,801 per
QALY gained for the 70 to 74 years age group; and $94,538 per life-
year gained and $90,405 per QALY gained for the 80þ years age
group. In the 75 to 79 years age group, the ICER for non–anthracy-
cline-based chemotherapy versus no chemotherapy was $14,137 per
life-year gained and $10,259 per QALY gained and anthracycline-
based chemotherapy was dominated when quality of life was
considered. Censoring-adjusted total health care costs did not
change the basic cost-effectiveness conclusions. The ICER estimates
increased but were within the commonly referenced benchmark ofTable 4 – Effectiveness and cost-effectiveness for chemo
Chemotherapy
treatment group
Effectiveness
Median life-
years (95% CI)
Median QALY
(95% CI)
65–69 y
No chemotherapy 11.21 (9.26–13.58) 13.71 (10.25–18.35)
Anthracycline-based 15.86 (12.75–19.73) 21.91 (15.71–30.57)
Non–anthracycline-
based
13.85 (11.25–17.06) 17.99 (13.14–24.63)
70–74 y
No chemotherapy 8.85 (7.70–10.09) 7.97 (6.75–10.24)
Anthracycline-based 10.97 (8.99–14.01) 10.42 (8.94–NA)
Non–anthracycline-
based
9.11 (8.64–11.36) 8.70 (7.51–12.23)
75–79 y
No chemotherapy 6.07 (5.24–7.14) 5.17 (4.28–6.45)
Non–anthracycline-
based
8.00 (5.78–9.58) 7.81 (5.46–10.03)
Anthracycline-based 8.15 (6.95–9.51) 7.18 (6.48–NA)
80þ y
No chemotherapy 5.12 (3.62–6.46) 4.26 (2.64–5.53)
Non–anthracycline-
based
4.47 (3.40–5.86) 3.50 (2.31–4.72)
Anthracycline-based 5.63 (4.23–7.64) 4.79 (3.31–6.75)
CI, conﬁdence interval; ICER, incremental cost-effectiveness ratio; NA, n
* Treatment groups arranged in ascending order of cost.
† 2013 US dollars.$100,000/QALY, except for the 80þ years age group in which the
ICER/QALY was marginally over the benchmark (data not shown).Discussion
This study examined the effectiveness and cost-effectiveness of
chemotherapy for older women with breast cancer stratiﬁed by age
within a large community cohort of patients treated from 1992 to
2009 in the United States. The results largely conﬁrmed the ﬁndings
from a previous, more restrictive randomized clinical trial that
reported that overall treatment effectiveness declined with age and
anthracycline-based chemotherapy was cost-effective relative to
non–anthracycline-based chemotherapy and no chemotherapy [5].
Age group–speciﬁc results show that anthracycline regimens
were most cost-effective for people aged 65 to 69, 70 to 74, and 80þ
years, but non–anthracycline-based regimens were most cost-
effective for people aged 75 to 79 years, especially when quality
of life was considered. Comparing anthracycline to no chemo-
therapy for those aged 75 to 79 years, however, yielded an ICER of
$19,647 per QALY gained, also well within the commonly cited
WTP US threshold. Although remaining highly cost-effective, there
was a trend for the ICERs to more than double between the 65 and
69 years and the 70 and 74 years age groups when comparing no
chemotherapy to anthracycline-based therapy, with non–anthra-
cycline-based therapy being dominated in each case.
The trend for the two oldest age groups was for the anthracy-
cline ICER to approach the $100,000 benchmark while dominating
the non–anthracycline-based therapy in the 80þ years age group.
The oldest age groups beneﬁt from treatment, but gains in life-
years and QALYs are less than for younger groups. These out-
come trends with age differ from previous studies that incorpo-
rated few patients beyond the age of 70 years [14]. Our ICER
trends with age are consistent with a previous modeling study
with parameters based on a systematic literature review [5].therapy treatment groups*.
Total health
care cost† ($)
ICER ($)
Mean (SE) Per median life-
year gained
Per median
QALY gained
81,261 (3533.83) – –
112,358 (3866.88) 6,691 3,790
122,631 (4774.74) Dominated Dominated
90,617 (3964.34) – –
117,141 (3896.55) 12,500 10,801
127,956 (5860.94) Dominated Dominated
89,210 (3996.89) – –
116,385 (4862.09) 14,137 10,259
128,701 (5275.21) 76,213 Dominated
83,875 (9203.27) – –
119,304 (7037.37) Dominated Dominated
131,853 (6957.07) 94,538 90,405
ot available; QALY, quality-adjusted life- year; SE, standard error.
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Fig. 2 – Effectiveness of treatment groups by age categories.
(Color version of ﬁgure available online).
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non–anthracycline-based chemotherapy for the 75 to 79 years age
group may be because of the higher disease stage at diagnosis in
the older age groups and statistical variability in the data. About
75% of the cases were diagnosed at stage II/III in the 75 to 79 years
age group compared with 50% to 60% in the younger age groups.
On comparing anthracycline-based and non–anthracycline-based
groups, the probability of being cost-effective reaches only about
50% at a WTP of $200,000 per life-year gained. In all other
comparisons, the probability of treatments being cost-effective
for the 75 to 79 years age group and younger groups reach 90% or
95% at the $50,000 WTP threshold. There was therefore no
compelling economic evidence to favor non–anthracycline-based
chemotherapy for the 75 to 79 years age group. Both treatments
were very cost-effective compared with no chemotherapy.
A meta-analysis of 123 clinical trials found that long-term
outcomes of anthracycline- based chemotherapy compared with
no chemotherapy was unrelated to age up to age 70 years. In
contrast, the efﬁcacy of cyclophosphamide, methotrexate, and
ﬂuorouracil compared with no chemotherapy was inversely
related to age [14]. Results beyond age 70 years were not clear
because of the limited number of cases. Our results show an
inverse relationship between age and both median life-years and
QALYs gained. For example, Appendix Table 4 found at http://dx.
doi.org/10.1016/j.jval.2015.08.008 presents a median years of life
gained of 4.65 for the 65 to 69 years age group, 2.12 for the 70 to 74
years age group, 2.08 for the 75 to 79 years age group, and 0.51 for
the 80þ years age group. In addition to the limits imposed by the
length of life, one possible explanation for these ﬁndings was that
a lower dose of chemotherapy may be more commonly admin-
istered to elderly patients and/or there may be a lack of sensi-
tivity to chemotherapy in elderly patients with breast cancer. We
also found that the Kaplan-Meier–derived QALYs in the anthra-
cycline group were higher than the life-years although they were
not statistically different as conﬁdence intervals overlap. A
plausible reason for this ﬁnding was that quality-of-life adjust-
ments were not signiﬁcant (0.84–0.99 in the continuing phase),
and so the differences between life-years and QALYs were
minimal. When life-years were compared to the worst-case
scenario (highest quality-of-life adjustment), however, median
QALYs were lower than life-years but statistically insigniﬁcant.
Several studies have examined the economics associated with
the treatment of early stage breast cancer [4,6,50], but few have 1)
included a “no chemotherapy” group, 2) compared anthracycline-
based versus non–anthracycline-based regimens, and 3) exam-
ined results stratiﬁed by age group for older women, including
women beyond the age of 70 years.More recent studies have focused on comparisons of anthra-
cycline regimens with the addition of targeted therapies [52,53].
Campbell et al. [5] published a study with research questions
similar to ours, although it was based on a Markov model to
simulate the natural history of early breast cancer and the impact
of alternative chemotherapy regimens. The model used param-
eters from randomized clinical trials conducted in the United
Kingdom [54–56] and a systematic literature review [13]. They
compared no chemotherapy with a ﬁrst-generation regimen (i.e.,
non–anthracycline-based) with second-generation (anthracy-
cline-based regimen) and third-generation regimens (anthracy-
cline þ taxane–based regimen). Costs were estimated from
studies in the United Kingdom [57,58].
For older women, the third-generation treatment was most
cost-effective if they were estrogen receptor–positive and had a 10-
year recurrence rate of less than 53% to 54%. Between the 53% to
54% and 80% range, the second-generation therapy was the cost-
effective treatment, and above that level of risk, no chemotherapy
was optimal. Our study found similar results, although the patients
in the current study ranged from 65 to 80þ years. Anthracycline
(second- and third-generation therapies) dominated non–anthra-
cycline-based (ﬁrst-generation therapies) chemotherapy, and both
were found to be cost-effective relative to no chemotherapy. Of
note is that the ICERs were well below the commonly cited USWTP
thresholds of $50,000 to $100,000 per QALY for 65 to 69 and 70 to 74
years age groups. Non–anthracycline-based chemotherapy was
dominated in the 80þ years age group and the ICER for
anthracycline-based compared with no chemotherapy was near
the high end of the common US WTP range.
Markov models were developed on the basis of evidence from
the literature and the Breast Cancer International Research Group
trial to evaluate the cost-effectiveness of TAC (docetaxel, doxor-
ubicin, and cyclophosphamide) compared with FAC (ﬂuorouracil,
doxorubicin, and cyclophosphamide) in the treatment of early
node-positive breast cancer from the Canadian [4] and UK [50]
perspectives. In both cases, TAC was found to be cost-effective
compared with FAC by standard conservative WTP thresholds.
The UK study examined subgroups by age and found an incre-
mental cost per QALY of £13,718 for women younger than 50
years compared with £25,826 for women 50 years or older.
Our study has several limitations that should be considered
for interpretation of the ﬁndings. The primary concern was the
effects of selection bias and confounding by indication on the
study ﬁndings because patients were not randomly assigned into
one of the three chemotherapy groups. For example, age and
comorbidity may affect patient choice in regard to whether and
how much chemotherapy to undergo [59]. Age and comorbidity
are both available in the data and were used to construct the
propensity score–matched groups. We also stratiﬁed the analysis
by age group. Despite the use of 1:1:1 propensity score matching,
unmeasured or unknown factors may differ in ways that affect
patient outcomes in each of the comparison groups. In addition,
the use of propensity score matching approach reduces the
sample size, which may result in a selective population and not
represent the population. A more robust method of addressing
selection bias such as instrumental variable analysis may be
appropriate; however, ﬁnding a valid instrument is challenging
using observational data sets such as SEER-Medicare [60,61].
Our primary analysis combined stages I, II, and IIIa, which
may mask cost-effectiveness for the individual stages. A secon-
dary analysis in Appendix Table 4 shows results for stages II and
IIIa. We were unable to estimate median survival for all chemo-
therapy regimens for stage I because survival probability did not
reach 0.5. We found that the non–anthracycline-based group was
dominated in both stage II and IIIa and ICER per QALY for stage II
was $13,060 and for stage IIIa was $178,120 for anthracycline-
based chemotherapy versus no chemotherapy. These results are
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 0 7 0 – 1 0 7 8 1077in line with our age-speciﬁc results because most of the patients
in the 70 to 74 and 75 to 79 years age groups are in stage II
(Appendix Table 6) and in the 80þ years age group there are
relatively more patients in stage IIIa.
Cases from the SEER-Medicare data were not representative of
all cancer cases in the United States. The study also excluded
members of health maintenance organizations during the study
period, limiting its generalizability to those patients, but treat-
ment costs and survival may not differ between health main-
tenance organizations and other managed preferred provider
organization models of care that rely on fee-for-service payment
[62]. Because of smaller numbers, the subgroup analyses based on
age group should be considered cautiously, particularly for those
patients in the 80þ years age group. The results of the study
should also be interpreted in light of considerable changes that
occurred in breast cancer care over the period 1992 to 2009. For
example, docetaxel and trastuzumab were approved in 2004 and
2006, respectively, as adjuvant therapy for node-positive patients
with early breast cancer, which may have substantially increased
patients’ total cost. Trastuzumab was administered in 15.5% of
non–anthracycline-based group patients and in 9.3% of
anthracycline-based group patients, which may explain the mar-
ginally higher total health care cost for the non–anthracycline-
based group. Finally, costs were measured from a payer perspec-
tive on the basis of amounts Medicare paid for the services. It was
likely that societal costs, which include indirect costs, may not be
much different, given the retirement age of the study population.Conclusion
In conclusion, anthracycline-based chemotherapy was cost-
effective for treating early stage (stage I, II, or IIIa) breast cancer
among older patients when compared with non–anthracycline-
based chemotherapy and no chemotherapy. The cost per QALY
gained for anthracycline-based chemotherapy fell within con-
servative WTP thresholds of less than $100,000 for most age
groups. Age group–speciﬁc analysis conﬁrmed these results,
except for the 75 to 79 years age group.
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